@article{Kula_Hoca_Ahbab_Ataoglu_2019, title={Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis}, volume={15}, url={https://eujournal.org/index.php/esj/article/view/12080}, DOI={10.19044/esj.2019.v15n15p268}, abstractNote={Diabetic ketoacidosis is a rare but serious and life-threatening acute complication of diabetes mellitus. It is characterized by ketoacidosis with other findings and should be treated immediately. In this case, a 33-year-old diabetic patient who admitted to the emergency department with diabetic ketoacidosis is presented. The patient was prescribed empagliflozin (sodium glucose cotransporter inhibitor-2) a month ago. The SGLT-2 inhibitors have been approved for use in the treatment of type 2 DM and are still not used in the treatment of type 1 DM. There are such reports of unusual side effects related SGLT-2 inhibitors, in the literature and among them, ketoacidosis is a rare and important side effect.}, number={15}, journal={European Scientific Journal, ESJ}, author={Kula, Atay Can and Hoca, Emre and Ahbab, Suleyman and Ataoglu, H. Esra}, year={2019}, month={May}, pages={268} }